The reductions in HbA1c concentration and body weight observed with orforglipron were consistent with the results already reported in ACHIEVE-1 and ATTAIN-2, while the glycemic efficacy of semaglutide was consistent with the PIONEER phase 3 trials, indicating that trial conditions and execution were appropriate to detect treatment differences in this comparison, the researchers wrote
Facial fillers restore lost volume in areas like the cheeks and under the eye
Reconstitute in sterile bacteriostatic water as needed
In the SUSTAIN clinical trials, semaglutide OW achieved superior glycemic control and weight loss compared with several other classes of anti-diabetes medications (ADMs) [14,15,16,17,18], including canagliflozin, an SGLT2i [19]
Zheng H, Zhu H, Liu X, Huang X, Huang A, Huang Y